Roscovitine is a selective CDK inhibitor originally designed as anti-cancer agent, which has
also been shown to inhibit proliferation in vascular smooth muscle cells (VSMCs). However …

Roscovitine is a potent CDK inhibitor often used as a biological tool in cell-cycle studies, but
its working mechanism and real targets in vascular smooth muscle cells (VSMCs) remain …

Understanding the mechanisms inducing endothelial cell (EC) proliferation following tumor
microenvironment stimuli may be important for the development of antiangiogenic therapies …

Abnormal vascular smooth muscle cell (VSMC) proliferation contributes to the pathogenesis
of restenosis. Thus, drugs interfering with cell cycle progression in VSMC are promising …

Aim: The abnormal proliferation of vascular smooth muscle cells (VSMCs) in arterial walls is
an important pathogenic factor of vascular disorders such as atherosclerosis and restenosis …

The increased proliferation of vascular smooth muscle cells (VSMCs) in the arterial wall is a
critical pathogenic factor for vascular diseases such as atherosclerosis and restenosis after …

Background Diabetes exacerbates abnormal vascular smooth muscle cell (VSMC)
accumulation in response to arterial wall injury. Vinpocetine has been shown to improve …

BACKGROUND AND PURPOSE Roscovitine, a cyclin‐dependent kinase (CDK) inhibitor
that induces tumour cell death, is under evaluation as an anti‐cancer drug. By triggering …

Adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1), and E-selectin, play important roles in the initial stage of …

Vascular endothelial dysfunction and inflammatory response are early events during
initiation and progression of atherosclerosis. In vitro studies have described that CIT …